Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

(Reuters) - Eli Lilly investors and analysts ... Zepbound, the weight-loss version of diabetes drug Mounjaro, was approved in late 2023 and has had a meteoric rise since, with millions of ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Lilly said on a call with analysts that it still believed there was huge demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro from hundreds of millions of patients. The ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

After adjusting for one-time costs, Eli Lilly's adjusted earnings per share (EPS) of $5.32 topped expectations of $5.11. Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound ...